Veeva Systems announced that Lucid Diagnostics Inc. has selected Veeva Vault CDMS to provide electronic data capture (EDC), coding, and data cleaning in their upcoming study for EsoGuard in patients undergoing standard of care screening for, and management of, Barrett's esophagus or esophageal adenocarcinoma.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
199.1 USD | -0.71% | -0.23% | +3.41% |
Apr. 24 | Veeva Systems Insider Sold Shares Worth $681,116, According to a Recent SEC Filing | MT |
Apr. 16 | Veeva Systems Insider Sold Shares Worth $746,297, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.41% | 32.18B | |
+14.14% | 7.33B | |
+22.16% | 3.83B | |
-14.26% | 3.23B | |
-27.90% | 1.25B | |
-34.43% | 1.12B | |
+2.01% | 912M | |
-24.21% | 856M | |
-38.47% | 859M | |
-21.21% | 661M |
- Stock Market
- Equities
- VEEV Stock
- News Veeva Systems Inc.
- Lucid Diagnostics Selects Veeva Vault CDMS for EsoGuard® Study